(AXSM) Axsome Therapeutics - Ratings and Ratios
Auvelity, Sunosi, Symbravo, AXS-05
AXSM EPS (Earnings per Share)
AXSM Revenue
Description: AXSM Axsome Therapeutics
Axsome Therapeutics Inc (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The companys commercial product portfolio includes Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness, and Symbravo (AXS-07) for acute migraine treatment.
Key Performance Indicators (KPIs) to monitor Axsome Therapeutics include revenue growth from its commercial products, particularly Auvelity and Sunosi, as well as the progress of its pipeline assets, such as AXS-05, AXS-12, and AXS-14, through various stages of clinical trials. The companys ability to successfully navigate the FDA approval process and expand its product offerings will be crucial to its long-term success.
From a financial perspective, Axsome Therapeutics market capitalization stands at approximately $5.48 billion. The companys return on equity (ROE) is negative, indicating that it is currently unprofitable. As a result, traditional valuation metrics such as price-to-earnings (P/E) ratio are not applicable. Investors should focus on other metrics, such as revenue growth, cash burn rate, and pipeline progress, to gauge the companys potential for future growth.
The companys research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial for smoking cessation is a positive development, as it indicates a potential expansion of the drugs therapeutic applications. The progress of this trial, along with the companys other ongoing clinical trials, will be closely watched by investors and analysts.
From a technical analysis perspective, Axsome Therapeutics stock price is currently trading near its support level of $99.9. The stocks moving averages (SMA20, SMA50, and SMA200) are trending downward, indicating a bearish trend. Investors should monitor the stocks price action and adjust their strategies accordingly.
AXSM Stock Overview
| Market Cap in USD | 5,909m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2015-11-19 |
AXSM Stock Ratings
| Growth Rating | 75.6% |
| Fundamental | 28.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 6.29% |
| Analyst Rating | 4.74 of 5 |
AXSM Dividends
Currently no dividends paidAXSM Growth Ratios
| Growth Correlation 3m | 71.3% |
| Growth Correlation 12m | 63.6% |
| Growth Correlation 5y | 71.4% |
| CAGR 5y | 25.35% |
| CAGR/Max DD 3y | 0.70 |
| CAGR/Mean DD 3y | 1.60 |
| Sharpe Ratio 12m | -0.44 |
| Alpha | 7.95 |
| Beta | 0.978 |
| Volatility | 39.40% |
| Current Volume | 420.6k |
| Average Volume 20d | 564.8k |
| Stop Loss | 112.2 (-3.9%) |
| Signal | -1.58 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-246.9m TTM) > 0 and > 6% of Revenue (6% = 29.7m TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA 6.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 39.29% (prev 94.84%; Δ -55.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -120.6m > Net Income -246.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.4m) change vs 12m ago 3.93% (target <= -2.0% for YES) |
| Gross Margin 91.48% (prev 89.68%; Δ 1.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 83.34% (prev 53.17%; Δ 30.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -14.94 (EBITDA TTM -188.1m / Interest Expense TTM 13.2m) >= 6 (WARN >= 3) |
Altman Z'' -8.78
| (A) 0.30 = (Total Current Assets 536.6m - Total Current Liabilities 342.1m) / Total Assets 639.8m |
| (B) -1.92 = Retained Earnings (Balance) -1.23b / Total Assets 639.8m |
| warn (B) unusual magnitude: -1.92 — check mapping/units |
| (C) -0.33 = EBIT TTM -197.1m / Avg Total Assets 594.0m |
| (D) -2.17 = Book Value of Equity -1.23b / Total Liabilities 566.7m |
| Total Rating: -8.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.24
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -2.22% = -1.11 |
| 3. FCF Margin -25.99% = -7.50 |
| 4. Debt/Equity 2.57 = -0.11 |
| 5. Debt/Ebitda -1.00 = -2.50 |
| 6. ROIC - WACC -87.73% = -12.50 |
| 7. RoE -357.6% = -2.50 |
| 8. Rev. Trend 86.61% = 4.33 |
| 9. Rev. CAGR 121.5% = 2.50 |
| 10. EPS Trend -14.64% = -0.37 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of AXSM shares?
Over the past week, the price has changed by -9.68%, over one month by +6.92%, over three months by +14.83% and over the past year by +26.37%.
Is Axsome Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AXSM is around 122.41 USD . This means that AXSM is currently overvalued and has a potential downside of 4.82%.
Is AXSM a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AXSM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 176.8 | 51.4% |
| Analysts Target Price | 176.8 | 51.4% |
| ValueRay Target Price | 137.5 | 17.8% |
Last update: 2025-09-16 04:31
AXSM Fundamental Data Overview
CCE Cash And Equivalents = 303.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 370.3704
P/S = 11.9373
P/B = 80.8667
Beta = 0.533
Revenue TTM = 495.0m USD
EBIT TTM = -197.1m USD
EBITDA TTM = -188.1m USD
Long Term Debt = 117.5m USD (from longTermDebt, last quarter)
Short Term Debt = 70.3m USD (from shortTermDebt, last quarter)
Debt = 187.9m USD (Calculated: Short Term 70.3m + Long Term 117.5m)
Net Debt = -87.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.79b USD (5.91b + Debt 187.9m - CCE 303.0m)
Interest Coverage Ratio = -14.94 (Ebit TTM -197.1m / Interest Expense TTM 13.2m)
FCF Yield = -2.22% (FCF TTM -128.7m / Enterprise Value 5.79b)
FCF Margin = -25.99% (FCF TTM -128.7m / Revenue TTM 495.0m)
Net Margin = -49.88% (Net Income TTM -246.9m / Revenue TTM 495.0m)
Gross Margin = 91.48% ((Revenue TTM 495.0m - Cost of Revenue TTM 42.2m) / Revenue TTM)
Tobins Q-Ratio = -4.71 (set to none) (Enterprise Value 5.79b / Book Value Of Equity -1.23b)
Interest Expense / Debt = 0.98% (Interest Expense 1.83m / Debt 187.9m)
Taxrate = 21.0% (US default)
NOPAT = -197.1m (EBIT -197.1m, no tax applied on loss)
Current Ratio = 1.57 (Total Current Assets 536.6m / Total Current Liabilities 342.1m)
Debt / Equity = 2.57 (Debt 187.9m / last Quarter total Stockholder Equity 73.1m)
Debt / EBITDA = -1.00 (Net Debt -87.7m / EBITDA -188.1m)
Debt / FCF = -1.46 (Debt 187.9m / FCF TTM -128.7m)
Total Stockholder Equity = 69.0m (last 4 quarters mean)
RoA = -38.59% (Net Income -246.9m, Total Assets 639.8m )
RoE = -357.6% (Net Income TTM -246.9m / Total Stockholder Equity 69.0m)
RoCE = -105.6% (set to none) (Ebit -197.1m / (Equity 69.0m + L.T.Debt 117.5m))
RoIC = -78.38% (NOPAT -197.1m / Invested Capital 251.5m)
WACC = 9.35% (E(5.91b)/V(6.10b) * Re(9.62%)) + (D(187.9m)/V(6.10b) * Rd(0.98%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.56%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -128.7m)
Revenue Correlation: 86.61 | Revenue CAGR: 121.5%
Rev Growth-of-Growth: -20.79
EPS Correlation: -14.64 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 58.46
Additional Sources for AXSM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle